论文部分内容阅读
目的探讨结直肠癌患者接受贝伐单抗联合化疗前后,外周血循环内皮细胞(CECs)与活性循环内皮细胞(aCECs)的变化及临床意义。方法选取2014年10月至2016年3月间内蒙古自治区人民医院收治的53例晚期肠癌患者为研究对象,另选取同期体检且各项指标正常的志愿者20人为对照。检测晚期结直肠癌患者采用贝伐单抗联合化疗前后与健康20人外周血CECs及aCECs。结果健康人CECs与aCECs明显少于晚期肠癌患者。完成治疗的28例患者中,临床获益(CR+PR)组治疗后CECs和aCECs均较治疗前明显减少,差异均有统计学意义(均P<0.05)。稳定(SD)组治疗前后,CECs变化不明显,差异无统计学意义(P>0.05);aCECs减少,差异有统计学意义(P<0.01)。进展(PD)组CECs和aCECs治疗后与治疗前均变化不大,差异均无统计学意义(均P>0.05)。结论联合检测CECs及aCECs可以预测贝伐单抗联合化疗治疗晚期结直肠癌的疗效。
Objective To investigate the changes and clinical significance of circulating endothelial cells (CECs) and circulating circulating endothelial cells (aCECs) in patients with colorectal cancer before and after bevacizumab combined with chemotherapy. Methods Fifty-three patients with advanced colorectal cancer who were admitted to People’s Hospital of Inner Mongolia Autonomous Region from October 2014 to March 2016 were enrolled in this study. Twenty healthy volunteers were enrolled in the study. To detect CECs and aCECs in peripheral blood of 20 patients with advanced colorectal cancer before and after bevacizumab combined with chemotherapy. Results CECs and aCECs in healthy people were significantly less than those in patients with advanced colorectal cancer. Among the 28 patients who completed the treatment, the CECs and aCECs in the clinically-benefited (CR + PR) group were significantly reduced compared with those before treatment (all P <0.05). There was no significant difference in CECs between the stable (SD) group before and after treatment (P> 0.05). The aCECs decreased, the difference was statistically significant (P <0.01). There was no significant difference in progress (PD) group between CECs and aCECs after treatment and before treatment (all P> 0.05). Conclusions The combined detection of CECs and aCECs can predict the efficacy of bevacizumab in combination with chemotherapy for advanced colorectal cancer.